Inflammatory bowel disease: Pathophysiology and current therapeutic approaches

Bincy P. Abraham, Tasneem Ahmed, Tauseef Ali

Research output: Contribution to journalArticlepeer-review

70 Scopus citations


Inflammatory bowel diseases, most commonly categorized as Crohn’s disease and ulcerative colitis, are immune mediated chronic inflammatory disorders of the gastrointestinal tract. The etiopathogenesis is multifactorial with different environmental, genetic, immune mediated, and gut microbial factors playing important role. The current goals of therapy are to improve clinical symptoms, control inflammation, prevent complications, and improve quality of life. Different therapeutic agents, with their indications, mechanisms of action, and side effects are discussed in this chapter. Anti-integrin therapy, a newer therapeutic class, with its potential beneficial role in both Crohn’s disease and ulcerative colitis is also mentioned. In the end, therapeutic algorithms for both diseases are reviewed.

Original languageEnglish (US)
Pages (from-to)115-146
Number of pages32
JournalHandbook of Experimental Pharmacology
StatePublished - Jan 1 2017


  • Adaptive immunity
  • Anti integrins
  • Anti-TNF drugs
  • Biologics
  • Corticosteroids
  • Crohn’s disease
  • Immunomodulators
  • Inflammation
  • Inflammatory bowel disease
  • Innate immunity
  • Mesalamine
  • Ulcerative colitis

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'Inflammatory bowel disease: Pathophysiology and current therapeutic approaches'. Together they form a unique fingerprint.

Cite this